# Retinal biomarkers for neurodegenerative disease
Eye-scan technologies that detect Alzheimer's and other neurodegenerative-disease biomarkers directly in the retina — a window onto brain pathology accessible without imaging the brain itself — spanning hyperspectral imaging, OCT-based structural biomarkers and retinal amyloid detection: RetiSpec and NeuroVision Imaging in North America, Optina Diagnostics in Canada, and Heidelberg Engineering in Germany.
Source: https://en.bioecon.ru/technology/retinal-biomarkers-neurodegenerative-disease/
Updated: 2026-08-18
## Overview and value chain
Markers: [EC: IVDR 2017/746 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]
Retinal biomarkers for neurodegenerative disease use eye-scan technologies to detect signals of Alzheimer's and related conditions directly in retinal tissue, exploiting the retina's direct neural and vascular connection to the brain as a non-invasive, accessible proxy for pathology that would otherwise require PET imaging or cerebrospinal-fluid sampling. RetiSpec's AI-driven hyperspectral eye test analyzes subtle spectral signatures in retinal tissue associated with Alzheimer's disease, with the company recently closing a $10 million USD round to advance commercialization and its underlying hyperspectral-imaging technology documented in a dedicated patent filing. Optina Diagnostics develops a related hyperspectral retinal-imaging approach for Alzheimer's biomarker detection, co-published in the same multi-site Alzheimer's Research & Therapy study and running an active registered clinical trial. Heidelberg Engineering's Spectralis OCT platform, an established retinal-imaging system originally built for ophthalmology, is now widely used as a research and clinical tool for OCT-based structural and vascular biomarkers linked to neurodegenerative disease, documented across multiple 2026 publications including JAMA Ophthalmology. NeuroVision Imaging's retinal amyloid-imaging technology targets amyloid-beta deposits detectable in the retina, part of the same expanding multi-site research literature validating retinal biomarkers against established Alzheimer's diagnostic measures.
The key directions of retinal biomarkers for neurodegenerative disease are:
1. **Hyperspectral retinal imaging (Hyperspectral Retinal Imaging):** capturing a full spectral signature (not just a color image) of retinal tissue to detect subtle Alzheimer's-associated changes invisible to conventional imaging — RetiSpec, Optina Diagnostics.
2. **OCT-based neurodegenerative biomarkers (OCT Neurodegenerative Biomarkers):** optical coherence tomography measuring retinal nerve fiber layer thickness and vascular density as structural proxies for neurodegeneration — Heidelberg Engineering's Spectralis platform.
3. **Retinal amyloid imaging (Retinal Amyloid Imaging):** detecting amyloid-beta deposits directly in retinal tissue, mirroring the amyloid pathology central to Alzheimer's diagnosis — NeuroVision Imaging.
4. **AI-driven multi-site biomarker validation (AI Retinal Biomarker Validation):** machine-learning classifiers trained and validated across multi-site clinical studies to establish retinal-biomarker correlation with confirmed neurodegenerative-disease status.
### Sectoral value chain
```
[retinal imaging technology development] ──> [multi-site clinical validation studies] ──> [regulatory clearance]
│
(clinical/screening deployment)
│
▼
[integration into neurodegenerative diagnostic pathway] <─── [AI biomarker classification & report] <─────┘
```
### Value chain levels
| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Imaging Technology Development** | engineering the hyperspectral, OCT or amyloid-ligand imaging hardware and its retinal-specific optics | **In:** target biomarker signal, optical engineering.
**Out:** retinal imaging device. |
| **Multi-site Clinical Validation** | correlating the retinal-imaging signal against PET/CSF-confirmed neurodegenerative-disease status across multiple study sites | **In:** imaging device, confirmed-diagnosis cohort.
**Out:** validated biomarker correlation data. |
| **Regulatory Clearance** | FDA 510(k)/PMA or EU IVDR/MDR review of the imaging device and its diagnostic claim | **In:** clinical validation data.
**Out:** cleared/CE-marked diagnostic device. |
| **Clinical/Screening Deployment** | the device is placed in an eye clinic, memory clinic or research center for patient scanning | **In:** cleared device.
**Out:** deployed screening capacity. |
| **AI Biomarker Classification** | a machine-learning classifier interprets the retinal scan to output a biomarker-positive/negative or risk-score result | **In:** retinal scan.
**Out:** biomarker classification result. |
| **Diagnostic Pathway Integration** | the retinal-biomarker result feeds into the broader neurodegenerative-disease diagnostic and monitoring pathway alongside cognitive testing and other biomarkers | **In:** biomarker result.
**Out:** integrated clinical assessment. |
Cross-cutting technologies of the sector:
- **Hyperspectral imaging (Hyperspectral Retinal Imaging):** capturing dozens to hundreds of spectral bands across the retina reveals tissue-composition changes invisible to standard RGB fundus photography, the core RetiSpec/Optina Diagnostics approach.
- **Optical coherence tomography (OCT Neurodegenerative Biomarkers):** high-resolution cross-sectional retinal imaging measures nerve fiber layer thinning and microvascular changes correlated with neurodegenerative disease progression.
- **Retinal amyloid detection (Retinal Amyloid Imaging):** imaging techniques targeting amyloid-beta deposits in retinal tissue provide a proxy for the amyloid plaque burden central to Alzheimer's pathology.
---
## US
North America hosts the leading commercial-stage retinal-biomarker companies, spanning hyperspectral imaging and amyloid-specific detection technologies.
### RetiSpec, NeuroVision Imaging, FDA
- **RetiSpec:** its AI-driven hyperspectral eye test analyzes retinal spectral signatures associated with Alzheimer's disease, recently closing a $10 million USD funding round to advance commercialization, with the underlying imaging technology documented in a dedicated patent filing.
- **NeuroVision Imaging:** develops retinal amyloid-imaging technology targeting amyloid-beta deposits detectable in retinal tissue, part of the expanding multi-site research literature validating retinal biomarkers against confirmed Alzheimer's diagnostic measures.
- **FDA framework:** retinal-biomarker imaging devices for neurodegenerative-disease detection remain predominantly in clinical-validation and research use, with FDA clearance requiring large multi-site studies correlating the retinal signal against PET or CSF-confirmed diagnosis.
---
## CN
No dedicated Chinese retinal-biomarker company for neurodegenerative disease cleared source confirmation as of 2026; the field's research literature in this period centers on general neurodegenerative-biomarker market analysis rather than a specific commercial retinal-imaging originator.
### research gap, NMPA pathway
- **Research and literature focus:** Chinese industry reporting on neurodegenerative biomarkers in 2026 covers the broader diagnostic-biomarker market rather than a retinal-imaging-specific commercial platform.
- **NMPA pathway:** any retinal-biomarker imaging device reaching Chinese clinical use would register with NMPA as a medical device, following the same validation-heavy pathway required in the US and EU given the early clinical-evidence stage of the category.
---
## EU
Germany anchors Europe's contribution through Heidelberg Engineering, whose established OCT platform has become a widely used research and clinical tool for retinal neurodegenerative biomarkers.
### Spectralis OCT, IVDR
- **Heidelberg Engineering:** its Spectralis OCT platform, originally built for ophthalmology, is now widely used as a research and clinical tool for OCT-based structural and vascular biomarkers linked to neurodegenerative disease, documented across multiple 2026 publications including JAMA Ophthalmology.
- **IVDR/MDR framework:** retinal-imaging devices sold in the EU require conformity assessment under the Medical Device Regulation (MDR 2017/745), with any paired diagnostic-software claim additionally subject to IVDR 2017/746.
---
## Leading companies and research institutes
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **RetiSpec** | 🇨🇦 Canada | *AI hyperspectral Alzheimer's eye test* | Patented hyperspectral imaging, $10M raise | growth |
| **Optina Diagnostics** | 🇨🇦 Canada | *Hyperspectral retinal imaging* | Multi-site Alzheimer's biomarker study | growth |
| **Heidelberg Engineering** | 🇩🇪 Germany | *Spectralis OCT platform* | OCT structural/vascular biomarkers | commercial |
| **NeuroVision Imaging** | 🇺🇸 USA | *Retinal amyloid imaging* | Amyloid-beta detection in retina | growth |
---
## Tech stack and innovations
The stack applies three distinct optical principles to the same underlying goal — reading neurodegenerative-disease pathology out of retinal tissue non-invasively — hyperspectral signature analysis, structural/vascular OCT imaging, and amyloid-specific detection.
1. **AI-driven hyperspectral analysis (Hyperspectral Retinal Imaging):**
- RetiSpec and Optina Diagnostics both capture full spectral signatures across the retina and apply machine-learning classifiers to detect subtle tissue-composition changes associated with Alzheimer's disease, validated in shared multi-site clinical research.
2. **OCT structural and vascular biomarkers (OCT Neurodegenerative Biomarkers):**
- Heidelberg Engineering's Spectralis platform measures retinal nerve fiber layer thickness and microvascular density, structural proxies increasingly correlated with neurodegenerative disease progression in published clinical research.
3. **Retinal amyloid detection (Retinal Amyloid Imaging):**
- NeuroVision Imaging's technology targets amyloid-beta deposits in retinal tissue, mirroring the amyloid-plaque pathology central to Alzheimer's diagnosis without requiring brain PET imaging.
4. **Multi-site clinical validation (AI Retinal Biomarker Validation):**
- RetiSpec and Optina Diagnostics' co-published, multi-site Alzheimer's Research & Therapy study illustrates the category's shared push toward large validated cohorts as the evidence bar for eventual regulatory clearance.
---
## Value chains and production pipelines
### Industrial pipeline of a retinal neurodegenerative biomarker device (FDA 510(k)/PMA / EU MDR-IVDR)
```
┌───────────────────────────┐ ┌───────────────────────────┐
│ 1. Imaging technology │ ───> │ 2. Multi-site clinical │
│ development │ │ validation │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 4. Clinical/screening │ <─── │ 3. Regulatory clearance │
│ deployment │ │ │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 5. AI biomarker │ ───> │ 6. Diagnostic pathway │
│ classification │ │ integration │
└───────────────────────────┘ └───────────────────────────┘
```
#### Stage 1: Imaging technology development
The hyperspectral, OCT or amyloid-ligand imaging hardware and its retinal-specific optics are engineered to capture the target biomarker signal from a routine, non-invasive eye scan.
#### Stage 2: Multi-site clinical validation
The retinal-imaging signal is correlated against PET- or cerebrospinal-fluid-confirmed neurodegenerative-disease status across multiple study sites, the evidence base RetiSpec and Optina Diagnostics' co-published research contributes to.
#### Stage 3: Regulatory clearance
The imaging device and its diagnostic claim undergo FDA 510(k)/PMA review or EU MDR/IVDR conformity assessment, with the category's early clinical-evidence stage meaning most platforms remain in validation rather than full clearance as of 2026.
#### Stage 4: Clinical and screening deployment
The cleared or research-use device is placed in an eye clinic, memory clinic or research center for patient scanning, integrating into existing ophthalmology infrastructure rather than requiring new imaging equipment.
#### Stage 5: AI biomarker classification
A machine-learning classifier interprets the retinal scan to output a biomarker-positive/negative call or a quantitative risk score, the step where RetiSpec and Optina Diagnostics' AI models operate.
#### Stage 6: Diagnostic pathway integration
The retinal-biomarker result feeds into the broader neurodegenerative-disease diagnostic and monitoring pathway alongside cognitive testing, blood-based biomarkers and, where available, PET imaging, offering a non-invasive and lower-cost screening layer ahead of more invasive confirmatory testing.